Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral) for early stage HER2-overexpressed/amplified breast cancer, neratinib in combination with capecitabine for advanced or metastatic HER2-positive breast cancer, and for HER2 mutation-positive solid tumors. Its products also include PB272 (neratinib, intravenous), and PB357.

At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care. 

We are thankful to be part of the HER2+ breast cancer community and are passionate about evaluating options that may benefit patients across the breast cancer therapy spectrum.

Puma Biotechnology, Inc.

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

COM:PUMABIOTECHNOLOGY

Puma Biotechnology, Inc.

Last Close

2.90

22/11 21:00

Market Cap

147.26M

Beta: -

Volume Today

536.92K

Avg: -

Analysis Not Available